There is a version of the GLP-1 compounding story that looks like regulatory hygiene. The shortage that justified compounding has been resolved. The FDA is restoring normal rules. Compounding pharmacies should not be making copies of patented drugs when the originals are available. That version is coherent and defensible.
There is another version that is harder to dismiss. The branded versions of semaglutide, tirzepatide, and liraglutide cost between $900 and $1,300 a month in the United States without insurance. The same drugs cost between $90 and $140 a month in Germany, France, and the United Kingdom. The molecule is identical. The manufacturing process is identical. The difference is the pricing structure of the American pharmaceutical market, which permits brand holders to charge whatever a given market will bear with minimal regulatory constraint on list price.
Compounding pharmacies entered this market during a genuine shortage — a period when patients with prescriptions could not obtain the branded product because Novo Nordisk and Eli Lilly could not produce enough of it to meet demand. The FDA permitted compounding under its shortage authority. Compounding pharmacies built supply chains, trained staff, and created a delivery infrastructure. Patients began using the compounded versions, including patients who could not have afforded the branded versions at any price. Telehealth platforms built businesses around the compounded product. Primary care physicians incorporated it into their practice.
Now the FDA has proposed to end that. The shortage, officially, is over. The branded products are available. The compounding justification, legally, has expired. Novo Nordisk and Eli Lilly have made clear they want the compounding pharmacies out of their market. Their lobbying position and the FDA’s regulatory proposal arrived in close proximity.
The pharmaceutical industry does not apologize for protecting its intellectual property. It is not required to. Patent protection for novel drugs is the explicit deal the federal government has made with the pharmaceutical sector in exchange for the investment required to develop new treatments. The argument is that without that protection, the investment would not happen and the drugs would not exist. That argument has merit. It does not fully explain a tenfold price difference between the United States and Germany for the same drug under the same patent.
The 1.5 to 2 million Americans currently using compounded semaglutide will now navigate a choice between a branded product at a price most of them cannot sustain and discontinuing a treatment that is managing real metabolic disease. Some will find insurance coverage. Most will not. The business that was built to serve them — and that served them well enough to attract millions of patients — is being dismantled by a regulatory process that is technically correct and practically devastating. Both of those things can be true at once. In the American pharmaceutical market, they often are.
Independent reporting. Real stories. No agenda but truth.
